JJJing-Min Ji

Jing-Min Ji

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jing-Min Ji has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Caige Li

    Department of Pathobiology and Immunology, Hebei University of Chinese Medicine, Shijiazhuang, 050200, China

    1 shared publication
  • Kai Fu

    Department of Otolaryngology Head and Neck Surgery, The Fourth Hospital of Hebei Medical University, 050000 Shijiazhuang, Hebei, China

    1 shared publication
  • Kun Yu

    Department of Pathobiology and Immunology, Hebei University of Chinese Medicine, 050200 Shijiazhuang, Hebei, China

    1 shared publication
  • Liyuan Hao

    Department of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, P. R. China

    1 shared publication
  • Qing Peng

    Department of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of China

    1 shared publication
  • Wei-Yi Wang

    Department of Pathobiology and Immunology, Hebei University of Chinese Medicine, 050200 Shijiazhuang, Hebei, China

    1 shared publication

Latest Publications

  • Open Access

    Dihydroartemisinin Suppressed Cell Migration and Promoted Autophagy through RALB in Tongue Squamous Cell Carcinoma

    by Yu-Man Zhang, Jing-Min Ji, Yan-Li Gong, Kun Yu, Wei-Yi Wang, Kai Fu

    Background: Overexpression of RAS-like proto-oncogene B (RALB), a member of the RAS-like Guanosine triphosphatase (GTPase) family, is significantly associated with poorer overall survival in patients with head and neck squamous cell carcinoma (HNSCC). However, potential drugs that inhibit RALB remain unknown. Methods: Differentially expressed genes (DEGs) in HNSCC were identified using the The Cancer Genome Atlas - Head and Neck Squamous Cell Carcinoma (TCGA-HNSC) dataset. Genes associated with the Rat sarcoma virus (RAS) signaling pathway were retrieved from the GeneCards database, the National Center for Biotechnology Information (NCBI) Gene resource, and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database. Subsequently, experimental validation was conducted using Cal-27 human tongue squamous cell carcinoma cells. First, wound-healing and colony-formation assays were performed, followed by treatment with dihydroartemisinin (DHA). Finally, an orthotopic xenograft model was established by implanting shRALB-Cal-27 cells into the tongues of BALB/c nude mice, which were then treated with DHA. Results: We found that RALB expression was correlated with N stage and closely related to patient survival in HNSCC. RALB knockdown promoted autophagyin Cal-27 cells. Moreover, DHA significantly inhibited the proliferation and migration in Cal-27 cells. DHA increased the expression levels of P62 and LC3B in the tongues of nude mice implanted with shRALB-Cal-27 cells. Conclusion: DHA inhibited migration and promoted autophagy through RALB in tongue squamous cell carcinoma (TSCC).

  • Open Access

    The Effects of Qinghao-Kushen and Its Active Compounds on the Biological Characteristics of Liver Cancer Cells

    by Jingmin Ji, Zhiqin Zhang, Qing Peng, Liyuan Hao, Yinglin Guo, Yu Xue, Yiwei Liu, Caige Li, Xinli Shi

    Background and Aims. Artemisia annua (Qinghao) and Sophora flavescens (Kushen) are traditional Chinese medicines (TCMs). They are widely used in disease therapy, including hepatocellular carcinoma (HCC). However, their key compounds and targets for HCC treatment are unclear. This article mainly analyzed the vital active compounds and the mechanism of Qinghao-Kushen acting on HCC. Methods. First, we chose a traditional Chinese medicine, which has an excellent clinical effect on HCC by network meta-analysis. Then, we composed the Qinghao-Kushen herb pair and prepared the medicated serum. The active compounds of Qinghao-Kushen were verified by the LC-MS method. Next, we detected key targets from PubChem, SymMap, SwissTargetPrediction, DisGeNET, and GeneCards databases. Subsequently, the mechanism of Qinghao-Kushen was predicted by network pharmacology strategy and primarily examined in HuH-7 cells, HepG2 cells, and HepG2215 cells. Results. The effect of the Qinghao-Kushen combination was significantly better than that of single Qinghao or single Kushen in HepG2 and HuH-7 cells. Qinghao-Kushen increased the expression of activated caspase-3 protein than Qinghao or Kushen alone in HepG2 and HepG2215 cells. Network analyses and the LC-MS method revealed that the pivotal compounds of Qinghao-Kushen were matrine and scopoletin. GSK-3β was one of the critical molecules related to Qinghao-Kushen. We confirmed that Qinghao-Kushen and matrine-scopoletin decreased the expression of GSK-3β in HepG2 cells while increased GSK-3β expression in HepG2215 cells. Conclusions. This work not only illustrated that the practical components of Qinghao-Kushen on HCC were matrine and scopoletin but shed light on the inhibitory of Qinghao-Kushen and matrine-scopoletin on liver cancer cells. Moreover, Qinghao-Kushen and matrine-scopoletin had a synergistic effect over the drug alone in HuH-7, HepG2, or HepG2215 cells. GSK-3β may be a potential target for HCC therapy.